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ABSTRACT: In this study we have developed biodegradable
polymeric nanoparticles (NPs) containing the cytostatic drugs
mertansine (MRT) or cabazitaxel (CBZ). The NPs are based on
chitosan (CS) conjugate polymers synthesized with different
amounts of the photosensitizer tetraphenylchlorin (TPC). These
TPC−CS NPs have high loading capacity and strong drug retention
due to π−π stacking interactions between the drugs and the
aromatic photosensitizer groups of the polymers. CS polymers with
10% of the side chains containing TPC were found to be optimal in
terms of drug loading capacity and NP stability. The TPC−CS NPs
loaded with MRT or CBZ displayed higher cytotoxicity than the
free form of these drugs in the breast cancer cell lines MDA-MB-
231 and MDA-MB-468. Furthermore, light-induced photochemical
activation of the NPs elicited a strong photodynamic therapy effect on these breast cancer cells. Biodistribution studies in mice
showed that most of the TPC−CS NPs accumulated in liver and lungs, but they were also found to be localized in tumors derived
from HCT-116 cells. These data suggest that the drug-loaded TPC−CS NPs have a potential in combinatory anticancer therapy and
as contrast agents.
1. INTRODUCTION
Cancer treatment by chemotherapy and radiotherapy still
suffers from systemic toxicity, drug resistance, and low
selectivity leading to an unsatisfactory outcome. Nanoparticles
(NPs) have been widely used to load diagnostic and
therapeutic agents, and one can benefit from their ability to
target into tumors via passive accumulation and active
targeting approaches. In particular, multimodal and theranostic
NPs combining treatment strategies and diagnostic imaging
have attracted huge interest.1 Porphyrins have been used as
theranostic agents in cancer treatment for photodynamic
therapy (PDT), photochemical internalization (PCI),2 photo-
thermal therapy,3 sonodynamic therapy,4 radiotherapy,5 for
diagnostic fluorescent imaging, magnetic resonance imaging,6
and photoacoustic imaging.7 Most porphyrins designed as
therapeutic agents are hydrophobic and form aggregates in
aqueous solution. Thus, porphyrins have been incorporated
into NPs to make them more suitable for tissue delivery.8,9
We have here developed a method for producing NPs
constituted by a polymer of photosensitizers conjugated to
chitosan (CS) that can be used both as carriers of cancer drugs
and for PCI and PDT against solid tumors. PCI is a technology
that utilizes amphiphilic photosensitizer molecules and light for
a site-specific release of endocytosed macromolecules or
chemotherapeutics into the cytosol.10,11 Combining PDT
with delivery systems for drug administration is being studied
by different research groups and has recently been reviewed.12
The toxic drugs used in this study, mertansine (MRT) and
cabazitaxel (CBZ), are incorporated into the NPs with the aim
of increasing the therapeutic effect, reducing systemic toxicity,
and at the same time having the possibility to exploit the
photodynamic properties of these NPs.
MRT is structurally similar to maytansine, a potent
anticancer agent that inhibits microtubule polymerization,
but a too narrow therapeutic window resulted in discontinua-
tion of its development.13 However, when coupled to the anti-
HER2 antibody trastuzumab, this antibody-drug conjugate is
one of four such substances approved for cancer treatment.14
Taxanes such as CBZ and paclitaxel are clinically approved
chemotherapeutic agents acting as mitotic inhibitors with
therapeutic efficiency against a range of solid tumors.15−17
Therapeutic application of these microtubule inhibitors is
hampered by dose-limiting toxic effects and by the hydro-
Received: January 15, 2020
Revised: February 24, 2020
Published: February 24, 2020
Articlepubs.acs.org/Biomac
© 2020 American Chemical Society
1489
https://dx.doi.org/10.1021/acs.biomac.0c00061
Biomacromolecules 2020, 21, 1489−1498
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,





















































































phobicity of the drugs. In this study, MRT and CBZ are loaded
into NPs made of CS, which is a biodegradable polysaccharide
derived from chitin. It is increasingly used in biomedical
applications including drug and gene delivery, tissue engineer-
ing, and as an antimicrobial substance.18,19 Interestingly, CS
has been shown to target breast cancer stem-like cells
overexpressing CD44 receptors.20
Polymer conjugates and NPs have been employed as drug
carriers to improve the solubility, stability, drug retention, and
to reduce the adverse effect of taxanes,21,22 and paclitaxel-
loaded polymeric NPs (Genexol) have been approved for
treatment of various cancers.23 Although current drug-
polymeric micellar NPs improve drug solubility and decrease
drug toxicity, their therapeutic efficacy is often comparable to
that of free drug.21
Pharmacokinetic studies of drug-loaded micelle NPs often
show rapid drug release in the circulation, probably due to a
combination of drug extraction and destabilization of the
NPs.24 It is hypothesized that albumin and lipoproteins in
blood are able to bind amphiphilic polymer molecules and
thereby disrupt the dynamic equilibrium of these NPs.25
It has been demonstrated that a block copolymer with a high
degree of aromatic monomer substitution formed micellar NPs
with enhanced stability and paclitaxel retention in blood
following intravenous injection. These properties were
attributed to noncovalent π−π stacking interactions between
the drug and the hydrophobic aromatic groups of the polymer
chains in the micellar core.26
In this study, we have exploited similar interactions between
NPs containing the photosensitizer tetraphenylchlorin (TPC)
bound to side chains of CS and the drugs MRT and CBZ.
TPC−CS conjugate polymers were synthesized by covalent
linking of varying amounts of lipophilic TPC as well as a
cationic moiety to glucosamine residues of the CS backbone,
as previously described.27 The TPC moieties contain aromatic
residues that will form stable hydrophobic π−π interactions
upon self-assembly of the TPC−CS polymers into micellar
TPC−CS NPs (Figure 1).
In this study, most experiments were performed using MRT-
loaded TPC−CS NPs on the two breast cancer lines MDA-
MB-231 and MDA-MB-468 to demonstrate uptake of these
NPs into cells, transport of the NPs into lysosomes, and the
cytotoxicity of the NPs on these cancer cells. To demonstrate
that other drugs than MRT can be loaded into the TPC−CS
NPs, we have performed some experiments using CBZ. One
experiment was also performed using the breast cancer cell line
MCF7, since these cells are expected to be resistant to
ferroptosis.28,29 Finally, in vivo biodistribution of the TPC−CS
NPs was quantified in liver, lungs, spleen, and tumors 4−72 h
after intravenous injection in mice.
2. EXPERIMENTAL SECTION
2.1. Materials. Ammonium acetate, dimethyl sulfoxide (DMSO),
liproxstatin-1, deferiprone and rabbit anti-LAMP1 (L1418) antibody
were purchased from Sigma-Aldrich, St. Louis, MO. Acetonitrile,
trifluoroacetic acid (TFA), and Tween-80 were from Fluka. MRT was
purchased from AbCam Inc. and CBZ from BioChemPartners. The
Amicon Ultra-15 ultrafiltration devices (Man. Cat. No. UFC901024)
were purchased from Merck Life Science (Millipore ab).
2.2. Methods. 2.2.1. Synthesis of Amphiphilic Meso-Tetraphe-
nylchlorin-Chitosan (TPC−CS) Conjugate Polymers. The polymers
were synthesized with varying amounts of the photosensitizer TPC,
that is, TPC was bound to 10%, 3% or 1% of the CS side chains. In
the studies performed to compare analyses or effects of these
conjugates, they are called TPC0.10-CS, TPC0.03-CS, and TPC0.01-CS,
respectively. Since most studies are performed with NPs made from
TPC0.10-CS, these NPs are then for simplicity called just TPC−CS.
Starting from a modified CS,30,31 chlorin-based TPC−CS conjugate
polymers were synthesized by linking the highly lipophilic photo-
sensitizer, TPC as well as cationic moieties such as 2-(N,N,N-
trimethylamino)acyl to the CS biopolymer, as detailed in the
Supporting Information, including Figures S1 and S2, and as
previously described in ref 27.
2.2.2. Nuclear Magnetic Resonance and Mass Spectrometry
Analyses. NMR spectra were recorded using a DRX 400 MHz Bruker
NMR spectrometer at 298 K. The chemical shifts are reported in parts
per million (ppm) relative to the residual proton signal (for 1H NMR)
and the carbon signal for (13C NMR) of the deuterated solvent used
[1H NMR: CDCl3 (7.26 ppm), DMSO-d6 (2.50 ppm);
13C NMR:
CDCl3 (77.16 ppm), DMSO-d6 (39.52 ppm)]. The acetone peak
(2.22 ppm) was used as the internal reference for D2O as solvents,
and all coupling constants are reported in Hertz. The identification of
aromatic protons characteristic for the porphyrin and chlorin ring
systems has previously been described.27 A Bruker Autoflex III or a
Bruker micro TOF-Q11 was used to obtain mass spectra. The
molecular masses were determined by high-resolution mass
spectrometry (HRMS) recorded on a Bruker micrOTOF-Q instru-
ment with electrospray ionization.
2.2.3. Preparation of Empty and Drug-Loaded TPC−CSNPs.
Although most experiments in the present study were performed
using MRT-loaded NPs, we decided to include some studies with
Figure 1. Synthesis of amphiphatic photosensitizer-chitosan (PS-CS)
conjugate polymers and their self-assembly into micellar nanoparticles
in aqueous buffers. The π−π stacking effect between aromatic groups
of the photosensitizer and the lipophilic drugs conferred increased
stability and loading capacity of the TPC−CS NPs.
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CBZ-loaded NPs to demonstrate that also other drugs can be loaded
into the TPC−CS NPs. The three TPC−CS conjugate polymers were
dissolved in 90% DMSO at a concentration of 8 mg/mL. Empty
TPC−CS micellar NPs were prepared by adding 1 mL of the TPC−
CS in DMSO rapidly to 10 mL of Milli-Q water (20 nm filter) under
agitation (5 min at 1000 rpm; room temp). MRT- or CBZ-loaded
NPs of these three TPC−CS polymers were prepared similarly, with
MRT or CBZ dissolved (0.8 mg/mL) in the TPC−CS DMSO
solution. The resulting NP dispersions were ultrafiltered using an
Amicon spin device (regenerated cellulose filter, MW cutoff 10 kDa; 4
spin cycles with 25-fold up-concentration) using phosphate-buffered
saline (PBS: 139 mM NaCl; 10.1 mM Na2HPO4; 1.8 mM NaH2PO4,
adjusted to pH 7.4) to remove DMSO and nonencapsulated drug.
2.2.4. Size Distribution and Zeta-Potential of NPs. The size
distribution of the NPs was measured using dynamic light scattering
(DLS) with a Malvern Zetasizer Nano-ZS (Malvern Instruments,
U.K.) and DTS software (version 4.20). The NPs were dispersed in
PBS buffer to polymer concentrations of 0.1−0.6 mg/mL and added
to microcuvettes. The size distributions are reported as Zave (nm) and
the polydispersity index (PDI). The zeta potential was measured
using the Malvern Zetasizer Nano-ZS equipped with a zeta-potential
cuvette. Size distribution and particle concentration of the TPC−CS
formulations were also measured by nanoparticle tracking analysis
(NTA) using a NanoSight 500 instrument: TPC−CS was diluted in
the amount of PBS (filtered through a 0.02 μM Anotop 25 filter)
needed to obtain a concentration within the recommended range (2
× 108 to 1 × 109 particles per mL). The samples were then loaded
into an NS500 instrument (Malvern Instruments Ltd., Worcester-
shire, U.K.). Five videos, each of 45 s, were acquired for every sample.
Videos were subsequently analyzed with the NTA 2.3 software, which
identifies and tracks the center of each particle under Brownian
motion to measure the average distance the particles move on a
frame-by-frame basis.
2.2.5. HPLC Quantification of MRT. To assess the quantity of
MRT contained within ultrafiltered (Amicon ultracel, MW cut off 10
kDa) TPC−CS micellar NPs, samples were treated with 45%
acetonitrile, 5% 0.02 M ammonium acetate (pH 5.5), and 50%
DMSO for 30 min at ambient temperature, followed by 2 min
vortexing. An Agilent 1290 system (Agilent, Waldbrunn, Germany)
setup with an Agilent mRP-C18 HiRes column (#5188−5231:5 μm
particle size, 4.6 × 50 mm length) was used at 25 °C for analyzing
MRT (10 μL was injected). The separation was performed using a
linear 0.5 mL/min flow gradient from 100% solvent A (90%
acetonitrile, 5% 0.02 M ammonium acetate, 0.1% TFA, 4.9% water)
to 90% solvent B (90% acetonitrile, 5% 0.02 M ammonium acetate,
0.1% TFA, 4.9% water) in 9 min. All samples were run in triplicates
with column recalibration for 5 min and blank runs between sample
injections. The MRT peak detected at 254 nm (Agilent 1100 VWD
G1314A) was observed after 0.6 min, and area-under-curve (AUC)
quantification of micellar MRT was calculated using a standard curve
obtained by injections of 0.225−3.6 mg/mL MRT; minimum S:N
10.0.
2.2.6. Cell Lines. Three commonly used breast cancer cell lines32
were used in this study: The MDA-MB-231 cell line (triple negative;
Claudin low; ductal) was cultured in RPMI 1640, the MDA-MB-468
(triple negative; basal) cell line was cultured in DMEM, and the
MCF7 (estrogen and progesterone-positive; ductal) cell line was
cultured in RPMI 1640. All media were fortified with 10% (v/v) fetal
calf serum albumin (Sigma) and 100 units/mL penicillin/
streptomycin (PenStrep, Sigma). The cell lines were obtained from
ATCC and were routinely tested for mycoplasma. Cells growing in
96-well plates were incubated with serial dilutions of free form of drug
(MRT, CBZ), empty- and drug-loaded TPC−CS NPs for 24, 48, or
72 h at 37 °C in an atmosphere of 5% CO2.
2.2.7. Cytotoxicity of Drug-Loaded TPC−CSNPs. The cytotoxicity
of empty polymeric NPs and MRT- and CBZ-loaded TPC−CS NPs
were evaluated by the commonly used MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay using free MRT (from
10 mM DMSO stock) and free CBZ (stock dissolved in Tween-80) as
control formulations. MDA-MB-231, MDA-MB-468, and MCF7cells
were seeded in 96-well plates (7 × 103 cells/well) and incubated for
24 h at 37 °C in a 5% CO2 humidified atmosphere. The empty and
drug-loaded NP formulations were briefly sonicated (Cole-Parmer
CP70T with microtip; 1 min; 2 s pulses at 40% output) and then
added to the cells in the corresponding cell culture media to the
different concentrations. The cells were incubated at 37 °C in CO2-
incubator for 18 h, then the cells were washed 3× with prewarmed
growth medium followed by a 4 h chase before light exposure of some
of the cells (5 min light dose with 420−435 nm light/13 mW/cm2;
LumiSource, PCI Biotech, Oslo, Norway). The cells were incubated
further at 37 °C in the CO2 incubator, and the cell toxicity was
determined after 48 or 72 h using the MTT assay.
2.2.8. Cellular Uptake of TPC−CS NPs Studied by Confocal
Fluorescence Microscopy. MDA-MB-231 cells (seeded 3 × 104 cells/
well in 24-well trays) were cultured on coverslips for 24 h prior to the
experiments. Cells were incubated with TPC−CS NPs (2 μg/mL) for
2 h in complete growth medium, followed by a 3× wash-out of
unbound NPs and chasing for 18 h at 37 °C. Then, the cells were
fixed in 10% (v/v) formalin for 15 min and permeabilized and
blocked in a 0.1% (v/v) TritonX-100 and 1% (w/v) bovine serum
albumin in PBS (“blocking buffer”) for 1 h at room temperature. The
fixed cells were immune-stained against the lysosomal marker LAMP-
1 with a primary rabbit anti-LAMP-1 antibody (diluted 1:200 in
blocking buffer) and followed by the secondary fluorescent donkey
antirabbit-alexa488 antibody conjugate (diluted 1:500). Coverslips
were mounted in Prolong Gold antifade reagent with DAPI (Life
Technologies). Immunolabeled cells were examined using a confocal
microscope (LSM 788; Carl Zeiss MicroImaging, Inc.) equipped with
a Neo-Fluar 63×/1.45 oil immersion objective or by super-resolution
structured illumination microscopy (SIM) imaging using a
DeltaVision OMX V4 Blaze 3D-SIM microscope. Image processing
and analysis were done with Zeiss LSM 510 software and Adobe
Photoshop CS4.
2.2.9. Experimental Animals. Female athymic nude foxn1nu mice
were bred at the Comparative Medicine Department, Oslo University
Hospital, and kept in a pathogen-free milieu at a constant temperature
(21.5 ± 0.5 °C) and humidity (55 ± 5%); 15 air changes/h and a 12
h light/dark cycle. The animals were 5−6 weeks old, and their weight
was 18−20 g before they were included in the experiments.
Anesthesia was obtained with 5% (v/v) Sevofluran along with 3 l
nitrous oxide and 1 l oxygen, given with breathing mask. Cages were
equipped with bedding, cardboard houses, and paper. Experiments
were approved by the National Animal Research Authority, after first
having been approved by the institutional veterinarian. All the
procedures involving animals were performed according to protocols
approved by the National Animal Research Authority and conducted
according to the regulations of the Federation of European
Laboratory Animals Science Association (PMID: 22776188). Food
and water were supplied ad libitum. Animals were sacrificed
performing cervical dislocation at the end of the experiments.
2.2.10. In Vivo Imaging. Empty or MRT-loaded TPC−CS NPs
were used to study biodistribution in subcutaneous thigh-located
HCT-116 tumor bearing mice using an in vivo imaging system IVIS
Spectrum (PerkinElmer, MA, U.S.A.). Mice were injected intra-
venously with either empty TPC0.10-CS or MRT-loaded (1 mg/mL)
TPC0.10-CS in 200 μL. The mice were given the above-mentioned gas
anesthesia using multiple masks. The excitation/emission wavelength
pair of 675/720 nm was used for imaging of the NPs. Full body
images were obtained 4, 24, 48, 72 h, and 21 days after injection; the
animals were then sacrificed and organs were harvested. Ex vivo
imaging of the organs was also performed with the IVIS Spectrum
using the same settings as above. Total signal intensity in the organs,
such as liver, spleen, kidneys, lungs, and tumors were calculated, using
Living Image software (PerkinElmer), as radiant efficiency (emission
light [photons/sec/cm2/str]/excitation light [μW/cm2] × 109) of the
region of interest, which was marked around the corresponding
organs. Organs from two animals from different treatment at each
time point were imaged. Epi-fluorescence color threshold was set
between 5.5 × 107 to 2.5 × 108 radiant efficiency for image analysis.
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3. RESULTS AND DISCUSSION
3.1. Synthesis of TPC−CS Conjugate Polymers with
Varying Amounts of TPC. Utilizing a protected CS, we
synthesized a key reactive electrophilic intermediate, which
facilitated the covalent chlorin modification on CS by a
nucleophilic substitution reaction, as detailed in the Supporting
Information and Figure S1. Since the reaction is quantitative,
we could synthesize TPC−CS with varying amounts of TPC,
that is, TPC−CS with 10%, 3%, or 1% of the side chains of CS
binding TPC. The remaining free bromide groups were then
replaced with the trimethylammonium group, simply by
reacting with an excess of trimethylamine. The final TPC−
CS conjugates were then obtained by deprotection under mild
acidic conditions, as detailed in Supporting Information. All
the final compounds were characterized by 1H NMR
spectroscopy (Figure 2) and the amount of TPC bound was
in each case calculated from the 1H NMR spectra according to
the previously reported procedure.27
3.2. Encapsulation of MRT in TPC−CS NPs. The TPC−
CS conjugates containing different amounts of TPC (10%, 3%,
and 1%) were mixed with MRT and solubilized in DMSO, and
then the DMSO solution was used to prepare dispersions of
MRT-loaded TPC−CS NPs by a self-assembly “nano-
precipitation” process in aqueous medium. The NP for-
mulations were subsequently ultrafiltered to remove DMSO
and unincorporated MRT. The micellar TPC−CS NPs with
lower amount of TPC (3% and 1%) formed larger NPs and
displayed a more polydisperse distribution (Zave: 175 nm; PDI:
0.45) than the NPs with 10% of TPC in the side chains
(Zave:110 nm; PDI: 0.25; Figure S3). This is likely because
fewer TPC molecules result in NPs with a more loosely packed
hydrophobic core.
Figure 2. 1H NMR spectra overlay of the TPC−CS conjugates. The spectra shown demonstrate the changes obtained when changing the degree of
substitution of the three formulations, that is, following conjugation of TPC to 1%, 3%, or 10% (from top to bottom) the side chains of CS.
Figure 3. Characterization of MRT-loaded TPC−CS NPs containing different amounts of TPC (0%, 1%, 3%, and 10%) bound to the side chains of
CS. (A) MRT encapsulation efficiency; mean MRT levels ± SD (n = 3) measured by HPLC. (B) Cytotoxicity of the different MRT-loaded TPC−
CS NPs. The cytotoxicity was measured using empty TPC0.1−CS, the three NPs carrying different amount of TPC−CS NPs loaded with 10%
MRT, or a similar dose of free MRT. The drug-loaded NPs were ultrafiltered to remove unincorporated MRT. MTT assay was performed in MDA-
MB-231 cells after 48 h incubation. The 5 min light pulse was given after 24 h exposure of the NPs. Mean values ± SD (n = 3).
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MRT loading and retention in the different micellar TPC−
CS NPs were studied by measuring the concentration of MRT
by HPLC and by their toxicity. The encapsulation efficiency of
MRT in the TPC−CS NPs with various degrees of substitution
of TPC was calculated from the HPLC data. The TPC0.10−CS
NPs loaded with 10% MRT showed an encapsulation
efficiency larger than 80% at an MRT feed concentration of
0.6 mg/mL compared to encapsulation efficiencies of 40% and
15% for TPC0.03−CS NPs and TPC0.01−CS NPs, respectively
(Figure 3A). This indicates that by increasing the amount of
TPC bound to CS, more MRT can be loaded and retained in
the TPC−CS, which can be explained by strong π−π stacking
and hydrophobic interactions between MRT and the hydro-
phobic chains of the TPC−CS conjugates.21 Moreover, a
decrease in encapsulation efficiency (to 70%) was measured
when TPC0.10−CS NPs were loaded with 20% MRT (Figure
S4). Thus, we did not attempt to further increase the loading
capacity of our TPC0.10−CS NP formulations. Illumination of
the MRT-loaded TPC0.10−CS NPs (5 min light dose),
followed by ultrafiltration, did not change the physiochemical
characteristics of the NPs nor did it result in an increased
release of MRT from the NPs (measured by HPLC; data not
shown).
Cytotoxicity of the three MRT-loaded NP formulations
(TPC−CS with 10%, 3% or 1% conjugation of TPC) was
similar when normalizing with their respective encapsulation
efficiencies, so that the actual concentrations of MRT added to
cells were plotted (Figure 3B). The cytotoxicity of MRT-
loaded TPC0.10−CS upon illumination (5 min pulse) was
similar to dark toxicity, except for the highest concentrations
where illumination caused higher toxicity due to a PDT effect
(see also Figure 5A). Moreover, the MRT-loaded TPC0.03−CS
and TPC0.01−CS also showed similar cytotoxicity in presence
and absence (not shown) of the illumination. Thus, no
significant increase in toxicity of MRT due to a light-induced
PCI effect was observed for any of the three different TPC−CS
NPs (Figure 3B). Moreover, no significant change in toxicity of
the three TPC−CS NP formulations was observed after 3 days
of storage and a new round of ultrafiltration (4 cycles of 20-
fold spin concentration/dilution; data not shown), indicating
that the three different TPC−CS NPs stably retained their
encapsulated MRT.
3.3. Characterization of TPC−CS NPs Loaded with
MRT or CBZ. The sizes (Zave) of the empty, MRT-, and CBZ-
loaded TPC0.10−CS NPs, as measured by DLS, were 112, 111,
and 110 nm, respectively (Figure 4), whereas NTA measure-
ments showed sizes of 133, 115, and 145 nm for the empty-,
MRT-, and CBZ-loaded TPC−CS NPs, respectively (Figure
S5). Thus, the formulations of MRT- and CBZ-loaded
TPC0.10−CS NPs had a size rather similar to the empty
TPC0.10−CS NPs. The zeta potential of all the TPC0.10−CS
formulations was +26 mV ± 4 (in PBS diluted 10 times with
water). In PBS supplemented with 10% fetal calf serum, the
zeta-potential changed to −9 mV, probably due to absorption
of serum proteins forming a corona on the surface of the
NPs.33,34 Based on size measurements, the NP formulations
were stable in water. Upon storage of the formulations for
more than 5 days in PBS some aggregates (200−500 nm)
could be measured, but a brief sonication disrupted the
aggregates and resulted in a size distribution similar to that of
newly made NPs (data not shown). Moreover, the TPC0.10−
CS NPs were stable, even when diluted to a polymer
concentration of less than 1 μg/mL, and did not change
within 24 h, measured as unaltered size and number of NPs by
NTA on the NanoSight instrument (data not shown).
3.4. Cytotoxicity of TPC−CS NPs with and without
Drug. The in vitro toxic effect of the drug-loaded TPC−CS
NPs compared to the free drug was assessed with MDA-MB-
231 and MDA-MB-468 cells using the MTT test. Toxicities of
the MRT-loaded TPC−CS NPs were higher than that of free
MRT in MDA-MB-231 cells (Figure 5A) and comparable to
that of free MRT in MDA-MB-468 cells (Figure 5B). The
cytotoxicity of the CBZ-loaded TPC−CS NPs was similar to
free CBZ in both MDA-MB-231 and MDA-MB-468 cells
(Figure 6A,B). The encapsulation of MRT and CBZ in TPC−
CS NPs did not reduce the potency of the drug in vitro,
indicating that encapsulated drug is efficiently released in cells.
Importantly, even though free drug may act as efficiently as the
drug-loaded NPs on cells, the drug encapsulation is likely to
improve the pharmacokinetics of the drugs and give less
adverse effects in vivo. Moreover, the toxicity of the TPC−CS
NPs loaded with either MRT or CBZ did not change after 4
months of storage at 4 °C and ultrafiltration, indicating a stable
level of both drugs in these NPs (data not shown).
Interestingly, in contrast to the toxicity of MRT and CBZ
that killed only 50−60% of these multidrug resistant breast
cancer cells, both the empty and drug-loaded TPC−CS NPs
elicited light-induced TPC-mediated phototoxicity (PDT
effect) that killed all cells (Figures 5 and 6). It is possible
that the toxicity elicited by the added drugs is partially masked
by a strong TPC−PDT effect in cell culture and that the drug
could be even more important in vivo. We showed that the
TPC0.10−CS NPs added to cells at low concentration (20 nM
MRT equiv) were able to induce a strong PCI effect of the
plant toxin gelonin (Figure S6), demonstrating that the TPC−
PC NPs elicited photochemical damage to endosomal
membranes thereby allowing cytosolic release of gelonin. In
future animal tumor growth inhibition experiments, it will be
interesting to investigate whether the injected drug-loaded
TPC−CS NPs will be efficient in tumor-targeted drug delivery
and to measure potential light dose-dependent PDT effects.
3.5. Ferroptosis as a Cell Death Mechanism. In this
experiment we included MCF7 cells, as we recently have
shown these cells to be resistant to ferroptosis induced by lipid
nanocapsules.28 Furthermore, MDA-MB-231 cells have been
shown to be vulnerable to PDT and concomitant lipid
peroxidation due to a low expression of the membrane-
associated glutathione-dependent lipid hydroperoxidase
(GPX4), whereas MCF7 cells have a high expression of
Figure 4. Size distributions of empty and drug-loaded TPC−CS NPs.
DLS measurements were performed using the Malvern Zetasizer
Nano ZS. The hydrodynamic diameters (Zave) determined for the
empty-, MRT-, and CBZ-loaded TPC−CS NPs was 112 ± 3, 111 ± 5,
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GPX4.29 Interestingly, a regulated type of necrosis called
ferroptosis has recently been discovered and found to be
associated with an iron-dependent accumulation of reactive
oxygen species, followed by formation of excessive amounts of
lipid hydroperoxides and loss of GSH.35 Lipophilic small-
molecule antioxidants have been shown to rescue cells from
Figure 5. Toxicities of empty-, MRT (10%)-loaded TPC0.1−CS NPs, and free drug in (A) MDA-MB-231cells and (B) MDA-MB-468 tumor cells
after exposure for 48 h, and ±light pulse (5 min) after 24 h. MTT assay was performed after 48 h incubation. The data are shown as percent of
control for each cell line not treated with TPC−CS NPs or MRT. The graphs show mean values ± SEM from three different experiments. *p <
0.05; ***p < 0.005 for comparison with empty TPC−CS NPs.
Figure 6. Toxicities of empty-, CBZ (10%)-loaded TPC0.1−CS NPs, and free drug in (A) MDA-MB-231cells and (B) MDA-MB-468 tumor cells
after exposure for 48 h, and ±light pulse (5 min) after 24 h. MTT assay was performed after 48 h incubation. The data are shown as percent of
control for each cell line not treated with TPC−CS NPs or MRT. The graphs show mean values ± SEM from three different experiments.
Figure 7. PDT effect of empty TPC−CS NPs upon treatment with ferroptosis inhibitors in the breast cancer cell lines MDA-MB-231 (A) and
MCF7 (B). The cells were incubated with TPC0.1−CS NPs for 24 h, followed by 1 h preincubation with liproxstatin-1 (Liproxst, 1 μM) or
deferiprone (DFP, 100 μM) before a 2 min light treatment. Toxicity of the treated cells was measured by the MTT assay after 48 h incubation. The
data are shown as percent of control for each cell line not treated with TPC−CS NPs. The graphs show mean values ± SEM from three
independent experiments. *p < 0.05; **p < 0.01; ***p < 0.005 for comparison of cells treated with Liprox, and ##p < 0.01; ###p < 0.005 for
comparison of cells treated with DFP.
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ferroptosis.36 To test whether the MDA-MB-231 and MCF7
cells (i.e., cells described to lack or to contain high levels of
GPX4, respectively) undergo ferroptosis upon light-induced
PDT by the TPC−CS NPs, we treated the cells with
ferroptosis rescue compounds. We found that the lipophilic
antioxidant liproxstatin-1 significantly rescued against PDT
toxicity of the TPC−CS NPs in MDA-MB-231 cells (Figure
7A), but had no effect in MCF7 cells (Figure 7B).
Furthermore, in agreement with ferroptosis being an iron-
dependent process, we observed that iron chelation with
deferiprone partially rescued MDA-MB-231 cells (Figure 7A),
but not MCF7 cells (Figure 7B). Thus, cell death by
ferroptosis may be involved in the PDT effect of the TPC−
CS NPs on some cancer cells. We suggest that efficient GPX4
inhibitors, such as RSL3 or FINO2,37,38 could be used in a
clinical setting in order to elicit a more efficient PDT effect by
sensitizing the cancer cells to undergo ferroptosis.
3.6. Uptake of the TPC−CS NPs in Breast Cancer
Cells. From earlier studies it is known that the TPC moieties
are tightly packed by stable hydrophobic π−π stacking
interactions in the “core” of the TPC−CS NPs, resulting in
a significant quenching (>12-fold) of the photosensitizer
fluorescence.27 Furthermore, uptake of the TPC−CS NPs and
accumulation in endocytic vesicles, together with light-induced
photochemical internalization (PCI), were demonstrated
through enhanced plasmid DNA transfection.27 Here, we
show that the TPC−CS NPs were endocytosed by the MDA-
MB-231 cells and displayed significant colocalization with
lysosomes after more than 4 h of incubation (Figure 8).
Moreover, the higher resolution of super illumination
microscopy (SIM) allowed the TPC−CS NPs to be observed
specifically localized along the inner membrane of the
lysosomes with little staining in their lumen. (Figure 8D,
inset). This suggests that the TPC−CS NPs have undergone
structural changes in the endolysosomal system such that the
amphipathic TPC−CS polymers become associated with the
inner leaflet of the lysosomal membrane. Furthermore,
confocal microscopy studies of TPC−CS NP cellular uptake
after various time points did not reveal any large increase in
TPC fluorescence over time that should be expected if the
TPC−CS NPs were gradually unfolded in endosomes causing
dequenching of the TPC fluorescence (data not shown). In
live-cell microscopy, we observed what happened to
fluorescent dextran colocalized with TPC−CS NPs in late
endosomes with increasing time of illumination (Figure S7):
The strong fluorescent signals of both dextran and TPC−CS in
endosomes rapidly faded (with 300 s of illumination),
indicating a TPC-induced rupture of the endosomes, allowing
endosomal escape of dextran. In control cells, where
fluorescent dextran localized to late endosomes (but without
TPC−CS NPs), the dextran signal did not fade, but was stably
retained in the endosomes.
3.7. In Vivo Biodistribution of TPC−CS NPs. Despite
the high level of fluorescence self-quenching of intact NPs, the
TPC−CS NPs become sufficiently unquenched after intra-
venous injection, permitting fluorescence imaging. Thus,
biodistribution of the TPC−CS NPs in HCT-116 tumor-
bearing mice was studied using the IVIS Spectrum Scanner
after 4, 24, 48, and 72 h (not shown), after which the mice
were sacrificed and organs harvested and subjected to ex vivo
imaging. Images of organs harvested 4, 24, 48, and 72 h after
injection with empty TPC−CS or MRT-loaded TPC−CS
(Figure 9A−D), and total radiant efficiency of the region of
interest per organ is plotted (Figure 9E−H). The majority of
fluorescence from both TPC−CS NP preparations were
recovered in the liver, consistent with observations for other
intravenously injected NPs.39 Significant amount of fluores-
cence was also recovered in spleen and lungs (similarly, as
observed for other NPs39). The significant accumulation of the
NPs in lungs may be because the lungs are the first capillary
network the NPs encounter after intravenous injection.
Furthermore, it has been reported that lung accumulation
might also be attributed to formation of aggregates in the
capillary network of the lungs.40 However, the TPC−CS NPs
did not display formation of aggregates in the presence of up to
50% FCS (in PBS), as determined by DLS-measurements
using the Zetasizer (data not shown). Positively charged NPs
have been described to be more prone to opsonization and
sequestration by macrophages in the lungs, liver and spleen.41
Furthermore, the pharmacokinetics of the TPC−CS NPs may
be changed and optimized by functionalizing them with
hyaluronic acid and/or PEGylation,42,43 resulting in longer
Figure 8. Uptake of MRT-loaded (A) or empty (B) TPC−CS NPs
(25 μg/mL) for 20 h in MDA-MB-231 cells. (C) Confocal
microscopy image with orthogonal views generated from a z-stack
of images. (D) SIM image showing TPC−CS micelles within
lysosomes (image taken 20 h after adding NPs), with TPC−CS
staining (red) along the periphery in many of the lysosomes (as in the
inset). Cells were incubated with TPC−CS NPs for 2 h, followed by a
wash-out and chasing for 18 h at 37 °C. Then the cells were fixed and
stained with an antibody against the lysosomal marker LAMP-1
(green). Nuclei are stained with DAPI (blue).
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circulation half-lives and hence to an improved tumor targeting
of the NPs.
Although the biodistribution data indicate that the tissue
accumulation of most NPs is completed within the first time
point of 4 h (Figure 9E), some increase in tissue fluorescence
was observed in liver, spleen, lungs, and tumors up to 24−48 h
after injection of both types of NPs (Figure 9F,G). This
increased fluorescence might be explained by dissolution of the
NPs over time resulting in release of TPC−CS polymers and
consequently dequenching of the TPC photosensitizer
fluorescence. A significant reduction in TPC fluorescence
was observed in all tissues 72 h postinjection (Figure 9H). The
fluorescence ceased after 21 days (not shown). This indicated
biodegradation of the TPC−CS NPs by enzymatic degradation
and excretion of the TPC−CS polymers.
It should be noted that although the tumor accumulation of
NPs is low, it is in the same range as we recently published for
other NPs, which had a very good effect on a patient-derived
xenograft model in mice,44 and also as reported in a review
article summarizing tumor accumulation data reported in 224
studies for different types of NPs.45
4. CONCLUSIONS
We have established a method for the preparation of NPs
based on the photosensitizer-conjugate polymers TPC−CS as
carriers of the lipophilic drugs MRT and CBZ. Three distinct
amphiphilic TPC−CS polymers with controlled amounts of
TPC bound at 10%, 3%, or 1% of the side chains of CS were
synthesized. The three TPC−CS polymers and the lipophilic
drugs self-assembled into NPs in an aqueous medium with a
hydrophobic core of aggregated π−π stacked TPC and drug
moieties and a shell of cationic polymer backbones. The
TPC−CS NPs with conjugation of TPC to 10% of the CS side
chains displayed the highest efficiency of MRT encapsulation
(>80%) and were chosen for further studies. Cytotoxicity
experiments in breast cancer cell lines show that the drug-
mediated toxicity is comparable or better than the free drug.
Additionally, the TPC−CS NPs showed a strong photo-
chemical (PDT) effect alone, and the toxic effect seemed to be
even stronger with the drug-loaded NPs. The TPC−CS NPs
are efficiently taken up by the cancer cells and localize along
with the inner leaflet of endolysosomal membranes, suggesting
structural changes of the NPs taking place following
endocytosis. The biodistribution pattern of TPC−CS NPs
reported here suggests that they are biodegradable and
promising candidates for delivery of hydrophobic drugs.
Possibly, they can also be used for enhanced tumor delivery
of anticancer drugs through light-induced photochemical
internalization and photodynamic therapy (PCI/PDT) effects.
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